1. Home
  2. ONC vs STT Comparison

ONC vs STT Comparison

Compare ONC & STT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • STT
  • Stock Information
  • Founded
  • ONC 2010
  • STT 1792
  • Country
  • ONC Switzerland
  • STT United States
  • Employees
  • ONC N/A
  • STT N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • STT Major Banks
  • Sector
  • ONC Health Care
  • STT Finance
  • Exchange
  • ONC Nasdaq
  • STT Nasdaq
  • Market Cap
  • ONC 26.9B
  • STT 25.8B
  • IPO Year
  • ONC N/A
  • STT N/A
  • Fundamental
  • Price
  • ONC $250.30
  • STT $109.35
  • Analyst Decision
  • ONC Strong Buy
  • STT Buy
  • Analyst Count
  • ONC 9
  • STT 12
  • Target Price
  • ONC $325.56
  • STT $113.00
  • AVG Volume (30 Days)
  • ONC 345.1K
  • STT 2.1M
  • Earning Date
  • ONC 08-06-2025
  • STT 07-15-2025
  • Dividend Yield
  • ONC N/A
  • STT 2.77%
  • EPS Growth
  • ONC N/A
  • STT 64.15
  • EPS
  • ONC N/A
  • STT 8.90
  • Revenue
  • ONC $4,175,868,000.00
  • STT $13,086,000,000.00
  • Revenue This Year
  • ONC $869.15
  • STT $4.72
  • Revenue Next Year
  • ONC $19.07
  • STT $3.25
  • P/E Ratio
  • ONC N/A
  • STT $12.32
  • Revenue Growth
  • ONC 51.16
  • STT 9.48
  • 52 Week Low
  • ONC $146.21
  • STT $72.81
  • 52 Week High
  • ONC $287.88
  • STT $110.97
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • STT 72.47
  • Support Level
  • ONC N/A
  • STT $108.83
  • Resistance Level
  • ONC N/A
  • STT $110.93
  • Average True Range (ATR)
  • ONC 0.00
  • STT 1.89
  • MACD
  • ONC 0.00
  • STT 0.24
  • Stochastic Oscillator
  • ONC 0.00
  • STT 86.47

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About STT State Street Corporation

State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2024, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.

Share on Social Networks: